Effects of a 48 hour continuous intravenous infusion of CGS 13080-primagrel, a selective thromboxane synthetase inhibitor, on the perinatal and early postnatal period in the guinea pig.
CGS 13080, imidazo[1,5-a]pyridine-5-hexanoic acid, was evaluated for perinatal and postnatal effects in third trimester pregnant guinea pigs and their offspring. The compound was administered via 48 hour continuous intravenous infusion to a group of pregnant guinea pigs (n = 16) at a dose of 3 mg/kg/hr starting on gestational day 52 (via chronically implanted indwelling jugular venous cannulas). A saline control group (n = 12) received equivalent volumes of normal saline 0.5 ml/kg/hr throughout the dosing period. A third group (surgery-sham, n = 16) was subjected to cannulation but not infused. A gross examination of each dam and piglets was conducted at necropsy on day 5 of lactation. The neonatal brains and all gross lesions (maternal and neonatal) were removed and fixed for histopathological examination. Compound-related clinical signs were noted in dams during the dosing phase of gestation. Six guinea pigs developed cephalic lymphatic swelling during the infusion. This observation may be correlated to the reported redistribution of fluid volume to the thorax of guinea pigs given intravenous injections of CGS 13080. There were no compound-induced effects on labor, delivery, or any of the examined reproductive parameters. There were no compound-related clinical signs, or effects on survival, body weight and developmental parameters in the F1 generation. Histopathological examination of the brains and other organs did not reveal any compound-related abnormalities. Based on these results, it was concluded that CGS 13080 did not elicit adverse perinatal and postnatal effects in guinea pigs.
Keith
J
J
Department of Biomedical Sciences, Virginia-Maryland Regional College of Veterinary Medicine, Virginia Polytechnic Institute and State University, Blacksburg 24061.
Rowles
T
T
Warwick
K
K
Yau
E
E
D000818:Animals; D001724:Birth Weight / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000196:embryology; D004334:Drug Administration Schedule; D004435:Eating / Q000187:drug effects; D005260:Female; D006168:Guinea Pigs; D007093:Imidazoles / Q000008:administration & dosage*; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000196:embryology; D007743:Labor, Obstetric / Q000187:drug effects*; D007774:Lactation / Q000187:drug effects*; D008099:Liver / Q000187:drug effects / Q000196:embryology; D008168:Lung / Q000187:drug effects / Q000196:embryology; D011247:Pregnancy; D011270:Pregnancy, Animal / Q000187:drug effects*; D011725:Pyridines / Q000008:administration & dosage*; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D007093:Imidazoles; D011725:Pyridines; C037787:pirmagrel; D013930:Thromboxane-A Synthase